News on the Division of Blood Diseases and Resources
|
News Release
NIH study finds lung function remained stable or improved in adults after transplant So-called low-intensity blood stem cell transplants, which use milder conditioning agents than standard stem cell transplants, do not appear to damage the lungs and may help improve lung function in some patients with sickle cell disease (SCD), according to a three...
|
NHLBI in the Press
The FDA has approved a novel blood filter for the emergency treatment of COVID-19. The filter, which targets a potentially fatal immune response, has shown promise in preliminary studies, according to researchers.
|
News Release
Initial investment aims to advance accessible and scalable candidate interventions into clinical trials within 10 years The National Institutes of Health plans to invest at least $100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease (SCD) and HIV. The Bill & Melinda Gates...
|
NHLBI in the Press
High blood pressure and elevated cholesterol levels in young adults may lead to an increased risk of heart disease later in life, even if they manage to get these levels down later in life, according to a new study.
|
Research Feature
A conversation with Dr. Kolapo Oyebola It is not lost on Kolapo Oyebola, Ph.D., that half the sickle cell disease cases worldwide can be found in his native Nigeria. This tragic fact, said the National Institutes of Health (NIH) postdoctoral fellow, has long been top of mind—and he is bent on doing something about it. Something big. He wants to...
|
News Release
A study of more than 1 million transfusion recipients does not suggest a change in red blood cell donation practices A new study has found that the sex or pregnancy history of red blood cell donors does not influence the risk of death among patients who receive their blood. The study adds to a growing body of literature examining whether blood...
Credit:
Ernesto del Aguila III, National Human Genome Rese...
|
NHLBI in the Press
Researchers have optimized CRISPR-Cas9 technology, a gene editing approach revolutionizing medical research, to achieve therapeutic editing of the blood stem cell population.